FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900602011> ?p ?o ?g. }

• W2900602011 abstract "Successful treatment of latent tuberculosis infection (LTBI) is essential to reduce tuberculosis (TB) incidence rates in low-burden countries. This study measures treatment completion and determinants of non-completion of LTBI treatment in Norway in 2016. This prospective cohort study included all individuals notified with LTBI treatment to the Norwegian Surveillance System for Infectious Diseases (MSIS) in 2016. We obtained data from MSIS and from a standardized form that was sent to health care providers at the time of patient notification to MSIS. We determined completion rates. Pearson’s chi squared test was used to study associations between pairs of categorical variables and separate crude and multivariable logistic regression models were used to identify factors associated with treatment completion and adverse drug effects. We obtained information on treatment completion from 719 of the 726 individuals notified for LTBI treatment in 2016. Overall, 91% completed treatment. Treatment completion was highest in the foreign-born group [foreign-born, n = 562 (92%) vs Norwegian-born, n = 115 (85%), p = 0.007]. Treatment completion did not differ significantly between prescribed regimens (p = 0.124). Adverse events were the most common reason for incomplete treatment. We found no significant differences in adverse events when comparing weekly rifapentine (3RPH) with three months daily isoniazid and rifampicin (3RH). However, there were significantly fewer adverse events with 3RPH compared to other regimens (p = 0.037). Age over 35 years was significantly associated with adverse events irrespective of regimen (p = 0.024), whereas immunosuppression was not significantly associated with adverse events after adjusting for other variables (p = 0.306). Treatment under direct observation had a significant effect on treatment completion for foreign-born (multivariate Wald p-value = 0.017), but not for Norwegian-born (multivariate Wald p-value = 0.408) individuals. We report a very high treatment completion rate, especially among individuals from countries with high TB incidence. The follow-up from tuberculosis-coordinators and the frequent use of directly observed treatment probably contributes to this. Few severe adverse events were reported, even with increased age and in individuals that are more susceptible. While these results are promising, issues of cost-effectiveness and targeting treatment to individuals at highest risk of TB are important components of public health impact." @default.
• W2900602011 created "2018-11-29" @default.
• W2900602011 creator A5002587461 @default.
• W2900602011 creator A5032135957 @default.
• W2900602011 creator A5033248082 @default.
• W2900602011 creator A5052594139 @default.
• W2900602011 creator A5061149195 @default.
• W2900602011 creator A5078524395 @default.
• W2900602011 creator A5080650318 @default.
• W2900602011 creator A5085447804 @default.
• W2900602011 date "2018-11-19" @default.
• W2900602011 modified "2023-10-10" @default.
• W2900602011 title "Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study" @default.
• W2900602011 cites W1524796444 @default.
• W2900602011 cites W1882177394 @default.
• W2900602011 cites W2028650055 @default.
• W2900602011 cites W2043904209 @default.
• W2900602011 cites W2046369265 @default.
• W2900602011 cites W2063268188 @default.
• W2900602011 cites W2088764977 @default.
• W2900602011 cites W2091672043 @default.
• W2900602011 cites W2112036202 @default.
• W2900602011 cites W2116048433 @default.
• W2900602011 cites W2123514774 @default.
• W2900602011 cites W2148232746 @default.
• W2900602011 cites W2149791683 @default.
• W2900602011 cites W2152022540 @default.
• W2900602011 cites W2166092946 @default.
• W2900602011 cites W2166112014 @default.
• W2900602011 cites W2168009523 @default.
• W2900602011 cites W2184272173 @default.
• W2900602011 cites W2293822362 @default.
• W2900602011 cites W2294775226 @default.
• W2900602011 cites W2320887466 @default.
• W2900602011 cites W2412311459 @default.
• W2900602011 cites W2516091697 @default.
• W2900602011 cites W2516710169 @default.
• W2900602011 cites W2588751641 @default.
• W2900602011 cites W2607016958 @default.
• W2900602011 cites W2617215549 @default.
• W2900602011 cites W2737368770 @default.
• W2900602011 cites W2740023892 @default.
• W2900602011 cites W2758939556 @default.
• W2900602011 cites W2766926881 @default.
• W2900602011 cites W2767129482 @default.
• W2900602011 cites W2778481507 @default.
• W2900602011 doi "https://doi.org/10.1186/s12879-018-3468-z" @default.
• W2900602011 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6245849" @default.
• W2900602011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30453946" @default.
• W2900602011 hasPublicationYear "2018" @default.
• W2900602011 type Work @default.
• W2900602011 sameAs 2900602011 @default.
• W2900602011 citedByCount "18" @default.
• W2900602011 countsByYear W29006020112019 @default.
• W2900602011 countsByYear W29006020112020 @default.
• W2900602011 countsByYear W29006020112021 @default.
• W2900602011 countsByYear W29006020112022 @default.
• W2900602011 countsByYear W29006020112023 @default.
• W2900602011 crossrefType "journal-article" @default.
• W2900602011 hasAuthorship W2900602011A5002587461 @default.
• W2900602011 hasAuthorship W2900602011A5032135957 @default.
• W2900602011 hasAuthorship W2900602011A5033248082 @default.
• W2900602011 hasAuthorship W2900602011A5052594139 @default.
• W2900602011 hasAuthorship W2900602011A5061149195 @default.
• W2900602011 hasAuthorship W2900602011A5078524395 @default.
• W2900602011 hasAuthorship W2900602011A5080650318 @default.
• W2900602011 hasAuthorship W2900602011A5085447804 @default.
• W2900602011 hasBestOaLocation W29006020111 @default.
• W2900602011 hasConcept C126322002 @default.
• W2900602011 hasConcept C138885662 @default.
• W2900602011 hasConcept C142724271 @default.
• W2900602011 hasConcept C151956035 @default.
• W2900602011 hasConcept C187212893 @default.
• W2900602011 hasConcept C188816634 @default.
• W2900602011 hasConcept C197934379 @default.
• W2900602011 hasConcept C2776991065 @default.
• W2900602011 hasConcept C2777975735 @default.
• W2900602011 hasConcept C2778607973 @default.
• W2900602011 hasConcept C2779806340 @default.
• W2900602011 hasConcept C2781069245 @default.
• W2900602011 hasConcept C2781413609 @default.
• W2900602011 hasConcept C41895202 @default.
• W2900602011 hasConcept C63428231 @default.
• W2900602011 hasConcept C71924100 @default.
• W2900602011 hasConcept C72563966 @default.
• W2900602011 hasConceptScore W2900602011C126322002 @default.
• W2900602011 hasConceptScore W2900602011C138885662 @default.
• W2900602011 hasConceptScore W2900602011C142724271 @default.
• W2900602011 hasConceptScore W2900602011C151956035 @default.
• W2900602011 hasConceptScore W2900602011C187212893 @default.
• W2900602011 hasConceptScore W2900602011C188816634 @default.
• W2900602011 hasConceptScore W2900602011C197934379 @default.
• W2900602011 hasConceptScore W2900602011C2776991065 @default.
• W2900602011 hasConceptScore W2900602011C2777975735 @default.
• W2900602011 hasConceptScore W2900602011C2778607973 @default.
• W2900602011 hasConceptScore W2900602011C2779806340 @default.
• W2900602011 hasConceptScore W2900602011C2781069245 @default.
• W2900602011 hasConceptScore W2900602011C2781413609 @default.
• W2900602011 hasConceptScore W2900602011C41895202 @default.
• W2900602011 hasConceptScore W2900602011C63428231 @default.

• next